The rapid and effective response to TNF-α blockade therapy further supported the “Type-2-low” classification, indicating that TNF-α inhibition could be a viable therapeutic option for refractory EGPA in patients with a history of “Type-2-low” asthma. The gene discussed is TNF; the disease is asthma.